Related Experiment Videos
Managing patients treated with bevacizumab combination therapy
Michael S Gordon1, David Cunningham
1Arizona Cancer Center, Greater Phoenix Area, Scottsdale, Ariz. 85258, USA. msgordon@u.arizona.edu
Oncology
|November 23, 2005
Summary
Bevacizumab (Avastin) targets vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis. While generally manageable, key side effects include hypertension, proteinuria, and rare arterial thrombosis, wound healing issues, or GI perforations.
Area of Science:
- Oncology
- Pharmacology
Background:
- Vascular endothelial growth factor (VEGF) is crucial for tumor angiogenesis.
- Bevacizumab is an anti-angiogenic agent designed to target VEGF.
- VEGF's limited role in adults suggests minimal side effects from its inhibition.
Purpose of the Study:
- To review the safety profile of bevacizumab based on published clinical trials.
- To focus on key adverse events associated with bevacizumab therapy.
Main Methods:
- Review of clinical trials, primarily in metastatic colorectal cancer.
- Analysis of bevacizumab's safety profile, focusing on specific adverse events.
Main Results:
- Key bevacizumab-related events include hypertension, proteinuria, arterial thrombosis, wound healing complications, bleeding, and gastrointestinal perforation.
- Most events are mild to moderate and manageable, with rare occurrences of serious complications.
- Bevacizumab exhibits a manageable side-effect profile.
Conclusions:
- Bevacizumab is a suitable adjunct to standard chemotherapy where efficacy is proven.
- Its distinct mechanism of action avoids typical cytotoxic agent toxicity.
- Bevacizumab is approved globally for therapeutic use.